m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04147)
Name
Resten-NG
Synonyms
Resten-NG (TN)
    Click to Show/Hide
Status
Phase 2
TTD Drug ID
D0M4MG
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Proto-oncogene c-Myc (MYC)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for Resten-NG. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Resten-NG through regulating the expression of Proto-oncogene c-Myc (MYC). [1], [2]
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for Resten-NG. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Resten-NG through regulating the expression of Proto-oncogene c-Myc (MYC). [2], [3]
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for Resten-NG. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Resten-NG through regulating the expression of Proto-oncogene c-Myc (MYC). [2], [4]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for Resten-NG. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Resten-NG through regulating the expression of Proto-oncogene c-Myc (MYC). [2], [5]
Insulin-like growth factor-binding protein 3 (IGFBP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for Resten-NG. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of Resten-NG through regulating the expression of Proto-oncogene c-Myc (MYC). [2], [5]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for Resten-NG. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Resten-NG through regulating the expression of Proto-oncogene c-Myc (MYC). [2], [6]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for Resten-NG. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Resten-NG through regulating the expression of Proto-oncogene c-Myc (MYC). [1], [2]
Methyltransferase-like 5 (METTL5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for Resten-NG. The Methyltransferase-like 5 (METTL5) has potential in affecting the response of Resten-NG through regulating the expression of Proto-oncogene c-Myc (MYC). [2], [7]
Wilms tumor 1-associating protein (WTAP)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for Resten-NG. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Resten-NG through regulating the expression of Proto-oncogene c-Myc (MYC). [2], [8]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for Resten-NG. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Resten-NG through regulating the expression of Proto-oncogene c-Myc (MYC). [1], [2]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for Resten-NG. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Resten-NG through regulating the expression of Proto-oncogene c-Myc (MYC). [2], [9]
References
Ref 1 Correlation of m6A methylation with immune infiltrates and poor prognosis in non-small cell lung cancer via a comprehensive analysis of RNA expression profiles. Ann Transl Med. 2021 Sep;9(18):1465. doi: 10.21037/atm-21-4248.
Ref 2 Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154. doi: 10.1155/2011/483154. Epub 2010 Dec 27.
Ref 3 N(6)-methyladenosine (m(6)A) reader IGF2BP1 accelerates gastric cancer aerobic glycolysis in c-Myc-dependent manner. Exp Cell Res. 2022 Aug 1;417(1):113176. doi: 10.1016/j.yexcr.2022.113176. Epub 2022 Apr 27.
Ref 4 LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2022 May 7;15(1):52. doi: 10.1186/s13045-022-01272-w.
Ref 5 The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells. Cancer Discov. 2021 Feb;11(2):480-499. doi: 10.1158/2159-8290.CD-20-0331. Epub 2020 Oct 6.
Ref 6 Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018 Mar;20(3):285-295. doi: 10.1038/s41556-018-0045-z. Epub 2018 Feb 23.
Ref 7 Ribosome 18S m(6)A methyltransferase METTL5 promotes pancreatic cancer progression by modulating c?Myc translation. Int J Oncol. 2022 Jan;60(1):9. doi: 10.3892/ijo.2021.5299. Epub 2021 Dec 31.
Ref 8 High Wilms' tumor 1 associating protein expression predicts poor prognosis in acute myeloid leukemia and regulates m(6)A methylation of MYC mRNA. J Cancer Res Clin Oncol. 2021 Jan;147(1):33-47. doi: 10.1007/s00432-020-03373-w. Epub 2020 Sep 3.
Ref 9 Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer. Mol Cell. 2021 Aug 5;81(15):3048-3064.e9. doi: 10.1016/j.molcel.2021.06.014. Epub 2021 Jul 2.